BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Enigma Diagnostics Announces Successful Completion of EU Framework 7 "RANGER" Project


7/18/2011 5:48:46 AM

OXFORD, England, July 18, 2011 /PRNewswire/ -- In October 2007, Enigma Diagnostics (Porton Down, UK & San Diego, USA) announced the award of a euro 3 Million grant by the European Commission Framework 7 programme. This EU Commission award was won in a competitive process and the grant was to support development of a rapid, fully automated molecular diagnostic system for Seasonal Influenza (circulating strains of Influenza types A & B) to be based on Enigma's concept ML (mini-laboratory) instrument system. The RANGER project started on 1st of July 2008 with a consortium of members. This was led by Enigma Diagnostics and included the UK Health Protection Agency (HPA) with responsibility for assay development, Sagentia (Harston, Cambridge, UK) supporting development of the Enigma® ML prototype system and Queen Sirikit National Institute of Child Health collecting samples for clinical trials. PERA administered the project on behalf of the consortium.

The concluding meeting of the RANGER consortium was held at Enigma's Oxford site on 30th June 2011 at which Enigma demonstrated the use of the Enigma® ML system from sample to result in less than 60 minutes, using a swab and running a Seasonal Influenza, real-time PCR assay.

John McKinley, Chairman of Enigma Diagnostics, said, "Enigma and all of the RANGER consortium recognise the valuable contribution of the EU Commission in supporting the successful development of the Enigma® ML system. This has progressed from initial design concept to pre-clinical assessment of the Seasonal Influenza test at the HPA Porton Down laboratories earlier this year. The Enigma® ML system will now move to the commercialization stage during 2012."

The Enigma® ML system will be showcased at AACC (American Association for Clinical Chemistry) at stand116 from 26th to 28th July 2011.

The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 201569.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma's innovative and proprietary technologies combine the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.

For more information visit www.enigmadiagnostics.com

Press Contact:
Tatjana Quinn
Telephone: + 44 (0)1235 854076
tatjana.quinn@enigmadiagnostics.com

SOURCE Enigma Diagnostics Limited



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES